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Ectopic lymphoid structures (ELS) often develop at sites of inflammation in target tissues 
of autoimmune diseases, such as rheumatoid arthritis, Sjögren’s syndrome, multiple 
sclerosis, myasthenia gravis, and systemic lupus erythematosus. ELS are characterized 
by the formation of organized T/B cells aggregates, which can acquire follicular dendritic 
cells network supporting an ectopic germinal center response. In this review, we shall 
summarize the mechanisms that regulate the formation of ELS in tertiary lymphoid 
organs, with particular emphasis on the role of lymphoid chemokines in both formation 
and maintenance of ELS, the role of emerging positive and negative regulators of ELS 
development and function, including T follicular helper cells and IL-27, respectively. Finally, 
we shall discuss the main functions of ELS in supporting the affinity maturation, clonal 
selection, and differentiation of autoreactive B cells contributing to the maintenance and 
perpetuation of humoral autoimmunity.
Keywords: tertiary lymphoid structures, autoimmunity, lymphoid chemokines, autoimmune diseases, ectopic 
germinal center
inTRODUCTiOn
It is now well appreciated that ectopic (or tertiary) lymphoid structures (ELS) can develop in target 
organs of several autoimmune diseases, which are sites of chronic inflammation, although they can 
also develop in association with cancer, infection, and graft rejection, as previously discussed (1). At 
particular mucosal sites, ELS can be named based on the site of inflammation where they occur, e.g., 
inducible bronchus-associated or gut-associated lymphoid tissue or iGALT and iBALT, respectively 
(2). ELS are characterized by aggregates of T and B cells often showing T/B segregation (i.e., separated 
areas within the aggregates densely populated by T or B cells only), development of high endothelial 
venules (HEVs), and, in the majority of cases, follicular dendritic cell (FDC) networks. Compared 
to lymphoid aggregates forming in secondary lymphoid organs (SLOs), ELS are transient structures 
that can be triggered by immunization or infection (3) and often resolve after antigen clearance (2). 
However, in autoimmune diseases, ELS mostly develop in the context of a chronic inflammation, 
contribute to maintain the disease process, and are often associated with a more severe disease course 
(1, 4). As we shall discuss later in this review, ELS developing in chronic autoimmune conditions 
are capable of activating the molecular machinery to sustain in situ antibody diversification, isotype 
switching, B cell differentiation, and oligoclonal expansion, which are in keeping with their ability 
to function as active ectopic germinal centers (GCs), which can also support the production of 
autoreactive plasma cells at the local site of inflammation.
The biological events that bring to ELS formation in disease tissues show numerous similarities 
with the signaling pathways involved in secondary lymphoid tissue organogenesis; nevertheless, 
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there are site-specific differences, particularly regarding the cel-
lular sources of the key factors regulating lymphoid neogenesis, 
which depend, at least in part, on the nature of the site of inflam-
mation (1, 2).
In this review, we shall first focus on the mechanisms regulat-
ing ELS formation and functions, including the well-established 
role of lymphoid chemokines and lymphotoxins (LTs) in ELS 
formation, together with the emerging importance of cytokines 
as positive (i.e., IL-21, IL-22) and negative (i.e., IL-27) regulators 
in ELS development, maintenance, and function. In the second 
part of this review, we shall discuss the evidence supporting 
the concept that ELS in autoimmune diseases contribute to the 
perpetuation and spreading of autoimmunity via the differen-
tiation autoantibody-producing cells selected for disease-specific 
antigens within ectopic GCs. We will mostly focus on rheumatic 
autoimmune diseases, such as rheumatoid arthritis (RA) and 
Sjögren’s syndrome (SS), but we will also refer to other organ-
specific autoimmune conditions to highlight differences in the 
antigen-driven process underlying ELS formation.
DeveLOPMenT AnD ORGAniZATiOn OF 
eLS: THe ROLe OF LYMPHOTOXinS AnD 
LYMPHOiD CHeMOKineS
The signals regulating ELS formation and perpetuation, mostly 
referred as lymphoid neogenesis, largely overlap with those 
regulating the same events in SLOs during embryonic life, known 
as lymphoid organogenesis, but with notable differences in the 
cellular sources of these factors in ELS development (5). Either 
in SLOs and ELS formation and perpetuation, the chemoattract-
ant signaling pathway involves several homeostatic lymphoid 
chemokines, such as CXCL13, CCL19, CCL21, and CXCL12, and 
their specific receptors CXCR5 (for CXCL13), CCR7 (for CCL19 
and CCL21), and CXCR4 (for CXCL12). In classic models of 
lymphoid organogenesis, the interaction between hematopoietic 
lymphoid tissue inducer cells (CD3−CD4+IL-7Ra+RANK+) and 
VCAM-1  +  ICAM-1  +  LTBR+ mesenchymal organizer cells 
drives the establishment of a LTα1β2 (also known as LTβ)/
lymphoid chemokine feedback loop, which is required for SLOs 
development including early B/T cell clustering and segregation 
as well as the differentiation of HEVs, as reviewed extensively 
elsewhere (1, 6, 7). Conversely, the early stages of lymphoid 
neogenesis in adult life are not fully understood, although recent 
evidence suggests an important role for inflammatory cytokines, 
such as IL-22 and IL-17, as early contributors in ELS formation, as 
discussed later. Regardless, once ELS are established, additional 
and/or alternative cell types can express lymphoid chemokines 
and LTs during chronic inflammation in autoimmune conditions. 
In ELS, myofibroblast-like stromal cells support the production 
of CCL21 around HEVs in the T cell-rich area of the lymphoid 
aggregate, whereas CXCL13 can be produced by infiltrating cells 
(i.e. CD14+ inflammatory monocytes, CD68+ macrophages, and 
memory CD3+CD4+ T cells) but also resident tissue cells such as 
activated stromal and epithelial cells (6). Therefore, it is believed 
that the immune cells recruited at the site of inflammation, in 
cross-talk with resident cells which are tissue-specific, exert an 
active role in the initiation of ELS development (2). Another 
example of the importance of the site-specific inflammatory 
milieu in ELS development and/or maintenance in autoimmune 
diseases is represented by TNF-α, which is abundantly expressed 
in the synovium of RA patients. In this regard, evidence that 
TNF-blockade can reverse ELS formation in the joints, at least 
in a subset of patients, would suggest that in some conditions, 
TNF-α can play a non-redundant role in ELS maintenance over 
and above LT-β (8).
Once ELS are established, lymphoid chemokines CCL19, 
CCL21, and CXCL13 are critical for their perpetuation and func-
tion by controlling the homing and tissue localization of immune 
cells subsets, which are crucial in adaptive immune responses. 
The concomitant presence of CCL19/CCL21 and peripheral node 
addressin (PNAd-positive) HEVs allows the homing of CCR7+ 
T  cells (i.e., naïve and central memory) and mature CCR7+ 
dendritic cells (DCs) from the systemic circulation upon bind-
ing to PNAd+ HEVs through L-selectin (6, 9). Naïve B cells can 
also express at lower level CCR7, and together with CXCR4 and 
CXCR5, they use these receptors to enter ELS from the systemic 
circulation (6, 10), although B cell positioning into ectopic fol-
licles is mainly controlled by CXCR5 in response to a CXCL13 
gradient. B cells can actively contribute to ELS maintenance as 
they become strong producers of LTβ.
Lymphoid chemokines CXCL13 and CXCL12 are also critical 
in the function of ELS as ectopic GCs by regulating the shut-
tling of B cells between the dark and light zones. Inside the GC, 
CXCL13, mostly produced by FDCs, mainly directs GC B cells to 
the light zone of the GC where antigen selection occurs. Within 
the GC, CXCL12, mostly produced by tingible body macrophages 
in ELS (11), is critically involved in the migration of CXCR4high 
centroblasts to the dark zone, where somatic hypermutation of 
the B cell receptor takes place (6). As discussed later in this review, 
in the target organs of autoimmune diseases, the formation of 
functional GCs as a result of the lymphoid neogenesis process 
is critical in the selection and differentiation of autoantibody-
producing B cells.
THe eMeRGinG ROLe OF CYTOKineS AS 
POSiTive AnD neGATive ReGULATORS 
OF eLS FORMATiOn, PeRPeTUATiOn, 
AnD FUnCTiOn
As mentioned earlier, besides the classic LT/lymphoid chemokines 
feedback loop, there is strong emerging evidence that cytokines 
produced in the context of the inflammatory process are also 
critically involved in the lymphoid neogenesis in autoimmune 
diseases. These include, not exhaustively, IL-17, IL-21, IL-22, 
IL-23, and TNF (2). For instance, IL-17 produced by a subset of 
podoplanin-expressing CD4 T cells has been strongly linked with 
ELS formation in animal models of inducible ELS, and the IL-23/
IL-17 axis has been recently associated with ELS formation in 
RA (12, 13). Because the role of IL-17 in ELS has been recently 
reviewed extensively (1, 2), here we will focus on the emerging 
role of positive and negative regulators of ELS formation and 
function such as IL-21/IL-22 and IL-27, respectively.
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Using a model of inducible ELS formation, autoimmunity and 
exocrine dysfunction resembling SS that we recently developed 
and which is triggered by local viral infection in the salivary 
glands of C57BL/6 mice (3), Barone et  al. demonstrated that 
the early production (i.e., within few hours from viral infection) 
of IL-22, a cytokine belonging to the IL-10 family, by γδT-cells 
first and by conventional CD4 T cells thereafter, was directly 
responsible for the induction of CXCL13 by a subset of resident 
stromal cells expressing gp38. Although IL-22 was able to induce 
CXCL13 in vitro in a LT-β-independent manner, it is yet to be 
established whether IL-22 is sufficient to induce ELS in vivo in the 
absence of lymphotoxins (12). These findings seem applicable to 
ELS forming in human autoimmune diseases, as IL-22 has been 
associated with the formation of inflammatory aggregates both 
in RA and SS (13, 14).
While IL-22 appears critical in the early phase of ELS devel-
opment, another cytokine, IL-21, a member of the common 
cytokine receptor γ chain-binding family, has been shown to play 
a fundamental role in the function of ELS as ectopic GCs. This 
cytokine is primarily produced by T follicular helper (Tfh) cells, a 
highly specialized subset of CD4+ memory T cells expressing high 
amount of CXCR5 (15) and thus able to migrate toward B cell 
follicles in response to CXCL13 production by FDCs.
In the last decade, Tfh cells have emerged as essential players 
in the regulation of B cell activation, antibody affinity matura-
tion, and the GC reaction via the expression of surface receptors 
such as inducible T-cell costimulator (ICOS) and programed 
cell death protein 1 (PD1). They also express the transcription 
factor B cell lymphoma protein 6 (Bcl-6), which promotes the 
expression of CXCR5 and represses other T-cell subset-specific 
transcription factors (16–18). IL-21 is the main soluble factor 
released by Tfh and binds a receptor complex consisting of 
the common γ chain and a unique IL-21R. On B cells, IL-21/
IL-21R interactions provide potent signaling for B-cell survival, 
proliferation, and differentiation (19). Indeed, the absence of 
Tfh cells impairs GC formation and the generation of long-
lived plasma cells, resulting in impaired high affinity antibody 
responses (20).
Among autoimmune diseases, elevated frequencies of Tfh 
cells in the peripheral blood have been demonstrated in RA, SS, 
multiple sclerosis (MS), myasthenia gravis (MG), and systemic 
lupus erythematosus (SLE) (21). Not surprisingly, IL-21 directly 
correlated with the frequency of Tfh-like cells. Both IL-21 level 
and number of Tfh-like cells were associated with higher titer of 
anti-CCP antibodies and disease activity score in RA (22). In the 
context of ELS, IL-21 and IL-21R expression are upregulated in the 
synovial tissue of RA patients, whereby IL-21 strictly segregates 
with the formation of ELS (23–25). Moreover, blocking IL-21/
IL-21R in animal models of RA and SS has a beneficial effect on 
the disease progression (26, 27).
Interestingly, plasticity between Th17 cells (but also Th1 and 
Th2) with Tfh cells has been observed (28) and may play an 
important role in autoimmune diseases, including models of 
experimental MS, whereby Th17 cells crossing the blood–brain 
barrier can acquire a Tfh-like cells phenotype, thus supporting 
ELS development and function in the central nervous system 
(2, 4). However, and of likely relevance to ELS and ectopic GC, 
Tfh2 and Tfh17, but not Tfh1, are able to secrete IL-21 and induce 
naïve B cells to secrete class-switched immunoglobulin (Ig) (28).
Together with positive regulators of ELS formation, the 
existence of cytokines exerting a negative role on lymphoid 
neogenesis, such as IL-27, has been recently described. IL-27 is 
a heterodimeric cytokine belonging to the IL-12 family and is 
composed of EBI3 and IL-27p28 (29). IL-27 signals through a 
receptor were composed of IL-27Rα and gp130, the latter used 
also by other cytokines such as IL-6 (29). IL-27 seems to be able 
to limit antibody production since overexpression of IL-27Rα 
in the MLR/lpr mouse model of lupus can ameliorate the anti-
body response (29). Moreover, it has been recently shown that 
IL27Rα−/− mice developed a more severe form of arthritis after 
immunization with methylated bovine serum albumin (mBSA), 
which was also characterized by multiple lymphoid aggregates 
forming in the inflamed synovial tissue (25). IL-27 can also 
restrict the expansion of Th17 cells and suppress secretion of 
IL-17, a cytokine associated also with survival and proliferation of 
B cells (25, 29, 30). In regard to ELS development, e.g., in human 
synovium, it has been observed that IL-27 is inversely correlated 
with the degree of lymphocytic infiltration in the inflamed tissue 
as well as with the expression of IL-17 and IL-21 at mRNA level 
(25). However, further experimental and mechanistic data will be 
required before exploiting the role of IL-27 as a negative regula-
tor of ELS formation and function for therapeutic purposes in 
autoimmune diseases.
THe ROLe OF eLS AS PeRPeTUATORS 
OF AUTOiMMUniTY in THe TARGeT 
ORGAnS OF AUTOiMMUne DiSeASeS
Ectopic lymphoid structures arise in the target organs of patients 
affected by autoimmune diseases, such as salivary glands in SS 
(6), synovial tissue in RA (31), kidneys in SLE (32), thymuses 
in MG (33), meninges in MS (34), and thyroids in Hashimoto’s 
thyroiditis (35) (Figure 1A). However, for reasons that are cur-
rently not clear, the frequency of ELS in these conditions varies 
significantly, from a minority of patients with SLE to virtually 
100% of patients with thyroiditis (36). For instance, in the RA 
synovium, the immune infiltrates can be arranged into three 
main microstructural levels of organization including (i) follicu-
lar synovitis with ELS (lymphoid pathotype, 40% of RA patients) 
(31, 37, 38); (ii) diffuse pattern of infiltration with a predominant 
macrophages component (myeloid pathotype); and (iii) pauci-
immune synovitis, characterized by a virtual absence of immune 
cells (fibroid pathotype) (39). Similarly, around 30–40% of 
patients with SS show ELS in the affected salivary glands (40, 41), 
and patients with ELS are significantly more likely to develop 
B-cell lymphomas of the mucosal-associated lymphoid tissue 
(MALT-L) (42, 43). In lupus nephritis, B/T cells aggregates can be 
found in up to 50% of patients in the tubulo-interstitium, but fully 
organized ectopic GC follicles are detectable in <10% of patients 
(44). As previously mentioned, ELS in autoimmune conditions 
are not only structurally reminiscent of SLOs but also functionally 
active as ectopic GC. There is now conclusive evidence that ELS in 
autoimmune diseases favor the affinity maturation of B-cells via 
FiGURe 1 | ectopic lymphoid structure (eLS) formation in autoimmune disease tissue. (A) Importance of lymphotoxins/lymphoid chemokines and 
inflammatory cytokines in the formation and maintenance of ELS in the target organs of patients with autoimmune diseases, where ELS preferentially drives the 
affinity maturation and clonal selection of autoantibodies toward specific autoantigens. (B) Summary table listing the main disease-specific autoantigens and the 
associated autoimmune disease where ELS formation has been observed.
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an antigen-driven selection process and their differentiation to 
plasma cells. B cell isolated from ELS in autoimmune conditions 
display highly somatically hypermutated Ig VH and VL regions 
in line with a local antigen-driven process (45–47). Furthermore, 
lineage tree analysis of the Ig gene repertoire of B-cells and 
plasma cells infiltrating ELS +  tissues in autoimmune diseases 
proved that clonal diversification and differentiation to antibody-
producing cells take place within ELS (45, 47, 48). In keeping 
with the above evidence, B cells within ELS display detectable 
activation-induced cytidine deaminase (49), the enzyme which 
regulates both somatic hypermutation and isotype class switching 
of the Ig genes (50).
Accumulating experimental data indicate that ELS in autoim-
mune diseases preferentially favor affinity maturation and clonal 
selection toward autoantigens, which are frequently the target of 
autoantibodies detectable in the patients’ circulation (Figure 1B). 
Specifically, ELS allow the selection and differentiation of auto-
reactive B cells into high-affinity plasma cells reacting against 
citrullinated antigens in RA (49), anti-ribonucleoproteins Ro/
SSA and La/SSB in SS (40), thyroglobulin and thyroperoxidase 
in Hashimoto’s thyroiditis (35), and insulin in type 1 diabetes 
(51, 52). More in details, we and other provided evidence that (i) 
perifollicular CD138+ plasma cells frequently bind biotinylated 
citrullinated fibrinogen and the Ro52 antigen in synovial and 
salivary gland ELS of RA and SS patients, respectively, but not 
vice versa, using double immunofluorescence experiments (40, 
49, 53, 54); (ii) the engraftment of ELS +  tissue from the RA 
synovium, SS salivary gland, and MG thymus in SCID mice in a 
series of chimeric human/murine models resulted in the release 
and detection of human autoantibodies against disease-specific 
autoantigens in the mouse circulation (54–56). More recently, 
(iii) by combining single B-cell sorting, Ig VH and VL gene clon-
ing, and recombinant monoclonal antibody production from 
ELS + RA synovia or from ACPA + RA synovial fluid, we and 
others demonstrated that around 30% of the synovial humoral 
response is directed toward citrullinated antigens (36, 48).
Thus, in conclusion, although the processes underlying ELS 
formation in autoimmune diseases largely follow a stereotyped 
lymphoid neogenesis process, the autoantigens driving the 
autoimmune response within ELS in the respective target organs 
appear to be disease specific. An important consequence of this 
phenomenon is that a better understanding of the fine specificity 
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of the autoantigens driving the autoimmune response within 
ELS would strongly enhance our knowledge of the underlying 
processes perpetuating autoimmunity and chronic inflammation 
in the different autoimmune diseases. Furthermore, and perhaps 
more importantly, the identification of dominant autoantigens 
driving B and T cell responses, as recently suggested by large 
throughput sequencing studies in the RA synovium, could 
pave the way for future vaccination and tolerogenic therapeutic 
 strategies (57, 58).
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